Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Korro Bio, Inc.NASDAQ: KRRO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $382K fell 68.8% year over year, behind the -7.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 60.5% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.
Context
- Depreciation & amortization amounted to 59.3% of revenue in FY2025, down 97.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -68.8% toward the trailing-twelve-month pace of -7.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.79M USD
- Year-over-year change
- +6.3%
- 4-year CAGR
- +24.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.79M | +6.3% |
| FY2024 | 2024-12-31 | 3.57M | -1.8% |
| FY2023 | 2023-12-31 | 3.63M | +44.6% |
| FY2022 | 2022-12-31 | 2.51M | +57.4% |
| FY2021 | 2021-12-31 | 1.6M | — |
Depreciation & Amortization vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 depreciation & amortization of $3.75M is the largest of the 11 companies compared; the peer median is $672K.
- Its year-over-year change of -7.8% is the 6th highest of 9, against a peer median of +7.7%.
- Depreciation & amortization amounts to 97.6% of revenue for KRRO, versus a peer median of 96.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.75M | -7.8% | +14.7% | 97.6% | |
| LTM Mar 2026 | $3.14M | +14181.8% | -37.6% | — | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.11M | -7.9% | -1.4% | — | |
| LTM Mar 2026 | $885K | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $674K | +14.4% | +24.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
| LTM Mar 2026 | $326K | +176.0% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| LTM Mar 2026 | $97.21K | -103.3% | -0.7% | 0.0% | |
| Peer median (excluding KRRO) | $672K | +7.7% | -0.7% | 96.0% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.96M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Depreciation & Amortization | 1.6M | 2.51M | 3.63M | 3.57M | 3.79M |
| Deferred Income Tax | 0 | (145K) | 0 | 0 | 0 |
| Stock-Based Compensation | 807K | 1.14M | 2.38M | 4.46M | 7.66M |
| Change in Working Capital | 904K | (633K) | 4.28M | 13.59M | (4.43M) |
| Accounts Receivables | 0 | 0 | 0 | (1.7M) | 727K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 56K | 1.76M | 3.1M | (1.34M) | (2.31M) |
| Other Working Capital | 848K | (2.39M) | 1.18M | 16.63M | (2.84M) |
| Other Non-Cash Items | (13.44M) | 1.51M | 3.6M | 1.89M | 31.68M |
| Operating Cash Flow | (32.09M) | (53.65M) | (67.28M) | (60.07M) | (78.56M) |
| Capital Expenditures | (4.45M) | (5.21M) | (7.84M) | (17.9M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.07M) | (37.21M) | 0 | (146.35M) | (26.19M) |
| Sales of Investments | 0 | 53.49M | 19M | 40.9M | 70.7M |
| Other Investing Activities | 13K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (39.5M) | 11.06M | 11.16M | (123.35M) | 43.99M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28K | 62K | 117.25M | 67.39M | 685K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | (44K) | 25.05M | 1.97M | 0 |
| Financing Cash Flow | 115.95M | 18K | 187.76M | 69.36M | 685K |
| Effect of Forex Changes | 0 | 0 | 0 | (4K) | 64K |
| Net Change in Cash | 44.35M | (42.57M) | 131.64M | (114.07M) | (33.82M) |
| Free Cash Flow | (36.54M) | (58.86M) | (75.12M) | (77.98M) | (79.08M) |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.